← All trials
NCT06372821
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2024
- Primary completion
- Feb 28, 2025
- Completion date
- Aug 31, 2025
- First posted
- Apr 18, 2024
- Last posted
- Apr 18, 2024
- Enrollment
- 10
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- University of WashingtonCollaborator
- Alzheimer's AssociationCollaborator
- Washington University in St. LouisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.